Furthermore, Poel and colleagues claimed that LUZP1 downregulation might mediate chemotherapy sensitivity mechanisms in colorectal cancer cells, potentially through cell cycle arrest (Poel et al., 2019). Here, LUZP1 is linked to colorectal cancer.